A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs BI 425809 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 25 Jan 2018 Status changed from suspended to recruiting.
- 04 Jan 2018 Planned End Date changed from 1 Feb 2019 to 5 Jul 2019.
- 04 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 7 Jun 2019.